Incyte Points To Niktimvo, Three Near-Term Approvals For Growth

 
• By Joseph Haas

With Jakafi slated to lose US patent protection in 2028, Incyte is looking to GVHD launch product Niktimvo and label expansions for Opzelura, Monjuvi and Zynyz to drive late-decade growth.

Incyte points to pending approvals, Phase III readouts and initiations as potential growth drivers (Shutterstock)

More from Earnings

More from Anticancer